Scholar Rock Holding (SRRK) Return on Capital Employed (2018 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Return on Capital Employed of 99.87% in Q1 2026, up 8.46% quarter-over-quarter from 109.1% in Q4 2025, and down 3280.0% on a YoY basis from 3.14% in Q1 2025.
Scholar Rock Holding (SRRK) Return on Capital Employed (2018 - 2026) Analysis & Trends
Scholar Rock Holding's Return on Capital Employed history runs 9 years deep, the most recent figure standing at 99.87% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 3280.0% year-over-year to 99.87%; the TTM figure through Mar 2026 stood at 99.87% (down 3280.0% YoY), while the FY2025 annual figure was 100.12%, down 2728.0% from the prior year.
- Return on Capital Employed was 99.87% for Q1 2026 at Scholar Rock Holding, up from 109.1% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 34.62% in Q3 2022 to a low of 141.01% in Q3 2024.
- Historically, Return on Capital Employed has averaged 76.71% across 5 years, with a median of 69.04% in 2023.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed sank 7311 bps in 2024, then jumped 2566 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 39.77% in 2022, then sank by 74 bps to 69.04% in 2023, then tumbled by 30 bps to 89.99% in 2024, then retreated by 21 bps to 109.1% in 2025, then gained by 8 bps to 99.87% in 2026.
- The last three Return on Capital Employed figures came in at 99.87% (Q1 2026), 109.1% (Q4 2025), and 115.35% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | -99.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -99.87% |
| Dec 31, 2025 | -109.10% |
| Sep 30, 2025 | -115.35% |
| Jun 30, 2025 | -99.99% |
| Mar 31, 2025 | -67.07% |
| Dec 31, 2024 | -89.99% |
| Sep 30, 2024 | -141.01% |
| Jun 30, 2024 | -97.91% |
| Mar 31, 2024 | -75.18% |
| Dec 31, 2023 | -69.04% |
| Sep 30, 2023 | -67.90% |
| Jun 30, 2023 | -59.48% |
| Mar 31, 2023 | -54.13% |
| Dec 31, 2022 | -39.77% |
| Sep 30, 2022 | -34.62% |
| Jun 30, 2022 | -40.19% |
| Mar 31, 2022 | -43.54% |
| Dec 31, 2021 | -54.79% |
| Sep 30, 2021 | -48.15% |
| Jun 30, 2021 | -38.38% |